177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

IntroductionProstate specific membrane antigen (PSMA), highly expressed in metastatic castration-resistant prostate cancer (mCRPC), is an established therapeutic target. Theranostic PSMA-targeting agents are widely used in patient management and has shown improved outcomes for mCRPC patients. Earlie...

Full description

Bibliographic Details
Main Authors: Ayman Abouzayed, Kamila Seitova, Fanny Lundmark, Vitalina Bodenko, Maryam Oroujeni, Vladimir Tolmachev, Ulrika Rosenström, Anna Orlova
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
PSMA
lutetium-177
PC3-pip cells
dosimetry
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1221103/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1221103/full

Similar Items